Pyxis Oncology, Inc. cash flow to debt ratio of -340.07% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Pyxis Oncology, Inc.'s free cash flow has decreased 9.67% from $-57.91M last year to $-63.51M, signaling decreasing performance

Pyxis Oncology, Inc.'s debt to equity ratio is 0.58, which means that the company's assets are healthy financed, signaling financial stability.

Pyxis Oncology, Inc.'s debt has increased relative to shareholder equity from 0.17 last year to 0.58 today, signaling weakened financials

Pyxis Oncology, Inc. has a net cash position, so leverage is healthy.

Pyxis Oncology, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Pyxis Oncology, Inc.'s profit margin has decreased (23.15%) in the last year from -478.95% to -589.80%, signaling decreasing performance

Pyxis Oncology, Inc.'s short-term assets of $72.11M exceed its short-term liabilities of $21.13M

Pyxis Oncology, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Pyxis Oncology, Inc.'s return on equity of -135.60%, is lower than 15.00%, indicating bad performance

Pyxis Oncology, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Pyxis Oncology, Inc. has insufficient public price history to evaluate earnings stability.

Pyxis Oncology, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Pyxis Oncology, Inc. has negative free cash flow, indicating cash burn

Pyxis Oncology, Inc.'s yearly earnings has decreased 2.96% since last year from $-77.33M to $-79.62M, signaling decreasing performance

Pyxis Oncology, Inc.'s yearly revenue has decreased 14.17% since last year from $16.15M to $13.86M, signaling decreasing performance

ROIC -173.38% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Pyxis Oncology, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Pyxis Oncology, Inc. had revenue growth in 4 out of 5 years, indicating consistent revenue performance

Pyxis Oncology, Inc. has insufficient public price history to evaluate ROE consistency.

Pyxis Oncology, Inc. has insufficient data to evaluate this check.

Pyxis Oncology, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Pyxis Oncology, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Pyxis Oncology, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Pyxis Oncology, Inc. has insufficient data to evaluate this check.

Pyxis Oncology, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Pyxis Oncology, Inc. has a price-to-book ratio of 7.78x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Pyxis Oncology, Inc. has a price-to-sales ratio of 17.54x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue